Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer

Savitha Sridharan1, Alakananda Basu1

  • 1Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

International Journal of Molecular Sciences
|February 15, 2020
PubMed

Insights

This review compares S6K1 and S6K2, two key targets in mechanistic target of rapamycin (mTOR) signaling. Understanding their distinct roles in breast cancer is crucial for developing effective mTOR-targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The mechanistic target of rapamycin (mTOR) pathway regulates crucial cellular processes like protein translation and metabolism.
  • mTOR complex 1 (mTORC1) is frequently dysregulated in cancers, including breast cancer, making it a therapeutic target.
  • Rapamycin and its analogs inhibit mTOR but show limited efficacy, necessitating a deeper understanding of downstream effectors.

Purpose of the Study:

  • To compare and contrast the expression, structure, regulation, and function of S6K1 and S6K2 in breast cancer.
  • To highlight the distinct roles of S6K1 and S6K2 in breast cancer pathogenesis.
  • To provide insights for developing more targeted and effective mTOR-based cancer therapies.

Main Methods:

  • Literature review and synthesis of existing research on S6K1 and S6K2.
  • Comparative analysis of structural homology and functional studies.
  • Examination of expression patterns and regulatory mechanisms in breast cancer contexts.

Main Results:

  • While structurally similar, S6K1 and S6K2 may exhibit distinct or even opposing functions in breast cancer.
  • Previous research has predominantly focused on S6K1, overlooking potential unique contributions of S6K2.
  • Both S6K homologs are implicated in breast cancer, but their specific roles and mechanisms may differ.

Conclusions:

  • A comprehensive understanding of S6K1 and S6K2 is essential for advancing mTOR-targeted breast cancer therapies.
  • Further research differentiating the roles of S6K1 and S6K2 could lead to improved therapeutic strategies.
  • Targeting specific S6K homologs may offer a more nuanced approach to inhibiting deregulated mTOR signaling in breast cancer.
Keywords:
RPS6KB1RPS6KB2S6K1S6K2breast cancermTOR

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

564
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K